首页 > 最新文献

Critical Reviews in Oncogenesis最新文献

英文 中文
Preface: Tumor-Associated Macrophages and Tumorigenesis: Therapeutic Targeting Strategies. 前言:肿瘤相关巨噬细胞与肿瘤发生:靶向治疗策略。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.1615/CritRevOncog.v29.i4.20
Benjamin Bonavida
{"title":"Preface: Tumor-Associated Macrophages and Tumorigenesis: Therapeutic Targeting Strategies.","authors":"Benjamin Bonavida","doi":"10.1615/CritRevOncog.v29.i4.20","DOIUrl":"10.1615/CritRevOncog.v29.i4.20","url":null,"abstract":"","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141580974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of TAMs in the Regulation of Tumor Cell Resistance to Chemotherapy. TAMs在调节肿瘤细胞对化疗的抗药性中的作用
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.1615/CritRevOncog.2024053667
Ryan McWhorter, Benjamin Bonavida

Tumor-associated macrophages (TAMs) are the predominant cell infiltrate in the immunosuppressive tumor microenvironment (TME). TAMs are central to fostering pro-inflammatory conditions, tumor growth, metastasis, and inhibiting therapy responses. Many cancer patients are innately refractory to chemotherapy and or develop resistance following initial treatments. There is a clinical correlation between the level of TAMs in the TME and chemoresistance. Hence, the pivotal role of TAMs in contributing to chemoresistance has garnered significant attention toward targeting TAMs to reverse this resistance. A prerequisite for such an approach requires a thorough understanding of the various underlying mechanisms by which TAMs inhibit response to chemotherapeutic drugs. Such mechanisms include enhancing drug efflux, regulating drug metabolism and detoxification, supporting cancer stem cell (CSCs) resistance, promoting epithelial-mesenchymal transition (EMT), inhibiting drug penetration and its metabolism, stimulating angiogenesis, impacting inhibitory STAT3/NF-κB survival pathways, and releasing specific inhibitory cytokines including TGF-β and IL-10. Accordingly, several strategies have been developed to overcome TAM-modulated chemoresistance. These include novel therapies that aim to deplete TAMs, repolarize them toward the anti-tumor M1-like phenotype, or block recruitment of monocytes into the TME. Current results from TAM-targeted treatments have been unimpressive; however, the use of TAM-targeted therapies in combination appears promising These include targeting TAMs with radiotherapy, chemotherapy, chemokine receptor inhibitors, immunotherapy, and loaded nanoparticles. The clinical limitations of these strategies are discussed.

肿瘤相关巨噬细胞(TAMs)是免疫抑制性肿瘤微环境(TME)中最主要的细胞浸润。TAMs 在促进炎症、肿瘤生长、转移和抑制治疗反应方面起着核心作用。许多癌症患者对化疗天生难治,或在初次治疗后产生抗药性。TME中的TAMs水平与化疗耐药性之间存在临床相关性。因此,TAMs 在导致化疗耐药性方面的关键作用引起了人们对靶向 TAMs 以逆转这种耐药性的极大关注。采用这种方法的先决条件是透彻了解 TAMs 抑制化疗药物反应的各种基本机制。这些机制包括增强药物外流、调节药物代谢和解毒、支持癌症干细胞(CSCs)抗药性、促进上皮-间质转化(EMT)、抑制药物渗透及其代谢、刺激血管生成、影响抑制性 STAT3/NF-κB 生存途径以及释放特定抑制性细胞因子(包括 TGF-β 和 IL-10)。因此,人们开发了多种策略来克服 TAM 调节的化疗抗药性。这些策略包括旨在消耗 TAMs、使其重新极化为抗肿瘤 M1 样表型或阻止单核细胞招募进入 TME 的新型疗法。目前以 TAM 为靶点的治疗效果并不理想,但结合使用以 TAM 为靶点的疗法似乎很有前景,这些疗法包括以 TAM 为靶点的放疗、化疗、趋化因子受体抑制剂、免疫疗法和负载纳米粒子。本文讨论了这些策略的临床局限性。
{"title":"The Role of TAMs in the Regulation of Tumor Cell Resistance to Chemotherapy.","authors":"Ryan McWhorter, Benjamin Bonavida","doi":"10.1615/CritRevOncog.2024053667","DOIUrl":"10.1615/CritRevOncog.2024053667","url":null,"abstract":"<p><p>Tumor-associated macrophages (TAMs) are the predominant cell infiltrate in the immunosuppressive tumor microenvironment (TME). TAMs are central to fostering pro-inflammatory conditions, tumor growth, metastasis, and inhibiting therapy responses. Many cancer patients are innately refractory to chemotherapy and or develop resistance following initial treatments. There is a clinical correlation between the level of TAMs in the TME and chemoresistance. Hence, the pivotal role of TAMs in contributing to chemoresistance has garnered significant attention toward targeting TAMs to reverse this resistance. A prerequisite for such an approach requires a thorough understanding of the various underlying mechanisms by which TAMs inhibit response to chemotherapeutic drugs. Such mechanisms include enhancing drug efflux, regulating drug metabolism and detoxification, supporting cancer stem cell (CSCs) resistance, promoting epithelial-mesenchymal transition (EMT), inhibiting drug penetration and its metabolism, stimulating angiogenesis, impacting inhibitory STAT3/NF-κB survival pathways, and releasing specific inhibitory cytokines including TGF-β and IL-10. Accordingly, several strategies have been developed to overcome TAM-modulated chemoresistance. These include novel therapies that aim to deplete TAMs, repolarize them toward the anti-tumor M1-like phenotype, or block recruitment of monocytes into the TME. Current results from TAM-targeted treatments have been unimpressive; however, the use of TAM-targeted therapies in combination appears promising These include targeting TAMs with radiotherapy, chemotherapy, chemokine receptor inhibitors, immunotherapy, and loaded nanoparticles. The clinical limitations of these strategies are discussed.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options. 晚期甲状腺髓样癌的治疗:目前的系统治疗方案
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.1615/CritRevOncog.2024051588
Mark A Jara

The current rapid development of more selective and effective drugs for the treatment of thyroid cancer has open a new era in the treatment of patients with this condition, in the past limited to the possibility of only radioactive iodine for well differentiated tumor and surgery for medullary thyroid carcinoma (MTC). The treatment of advanced medullary thyroid carcinoma has evolved in the last few years and options for patients with advanced disease are now available. Multikinase inhibitors (MKIs) with nonselective RET inhibition like Vandetanib and Cabozantinib were approved for the treatment of MTC, although the efficacy is limited due to the lack of specificity resulting in a higher rate of drug-related adverse events, leading to subsequent dose reductions, or discontinuation, and the development of a resistance mechanism like seen on the RET Val804 gatekeeper mutations. MTC is associated with mutations in the RET protooncogene, and new highly selective RET inhibitors have been developed including Selpercatinib and Pralsetinib, drugs that have demonstrate excellent results in clinical trials, and efficacy even in the presence of gatekeeper mutations. However, despite their efficacy and great tolerability, mechanisms of resistance have been described, such as the RET solvent front mutations. Due to this, the need of constant evolution and drug research is necessary to overcome the emergence of resistance mechanisms.

目前,用于治疗甲状腺癌的选择性更强、更有效的药物发展迅速,为甲状腺癌患者的治疗开创了一个新纪元。过去,对于分化良好的肿瘤,只能使用放射性碘,而对于甲状腺髓样癌则只能进行手术治疗。在过去几年中,晚期甲状腺髓样癌的治疗方法不断发展,晚期患者现在有了更多选择。具有非选择性RET抑制作用的多激酶抑制剂(MKIs),如凡达尼布(Vandetanib)和卡博赞替尼(Cabozantinib),已被批准用于治疗MTC,但其疗效有限,因为缺乏特异性,导致药物相关不良反应发生率较高,从而导致随后的剂量减少或停药,以及耐药机制的发展,如RET Val804守门员突变。MTC 与 RET 原癌基因的突变有关,目前已开发出新的高选择性 RET 抑制剂,包括赛乐替尼(Selpercatinib)和普乐替尼(Pralsetinib)。然而,尽管这些药物具有良好的疗效和耐受性,但也出现了耐药机制,如 RET 溶剂前突变。因此,要克服耐药机制的出现,就需要不断地进化和药物研究。
{"title":"Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options.","authors":"Mark A Jara","doi":"10.1615/CritRevOncog.2024051588","DOIUrl":"10.1615/CritRevOncog.2024051588","url":null,"abstract":"<p><p>The current rapid development of more selective and effective drugs for the treatment of thyroid cancer has open a new era in the treatment of patients with this condition, in the past limited to the possibility of only radioactive iodine for well differentiated tumor and surgery for medullary thyroid carcinoma (MTC). The treatment of advanced medullary thyroid carcinoma has evolved in the last few years and options for patients with advanced disease are now available. Multikinase inhibitors (MKIs) with nonselective RET inhibition like Vandetanib and Cabozantinib were approved for the treatment of MTC, although the efficacy is limited due to the lack of specificity resulting in a higher rate of drug-related adverse events, leading to subsequent dose reductions, or discontinuation, and the development of a resistance mechanism like seen on the RET Val804 gatekeeper mutations. MTC is associated with mutations in the RET protooncogene, and new highly selective RET inhibitors have been developed including Selpercatinib and Pralsetinib, drugs that have demonstrate excellent results in clinical trials, and efficacy even in the presence of gatekeeper mutations. However, despite their efficacy and great tolerability, mechanisms of resistance have been described, such as the RET solvent front mutations. Due to this, the need of constant evolution and drug research is necessary to overcome the emergence of resistance mechanisms.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preface. 序言
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.1615/CritRevOncog.v29.i3.30
Benjamin Bonavida, Stuart Samuels
{"title":"Preface.","authors":"Benjamin Bonavida, Stuart Samuels","doi":"10.1615/CritRevOncog.v29.i3.30","DOIUrl":"https://doi.org/10.1615/CritRevOncog.v29.i3.30","url":null,"abstract":"","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Convolutional Neural Networks for Glioma Segmentation and Prognosis: A Systematic Review. 卷积神经网络用于胶质瘤分割和预后:系统性综述
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.1615/CritRevOncog.2023050852
Janette Herr, Radka Stoyanova, Eric Albert Mellon

Deep learning (DL) is poised to redefine the way medical images are processed and analyzed. Convolutional neural networks (CNNs), a specific type of DL architecture, are exceptional for high-throughput processing, allowing for the effective extraction of relevant diagnostic patterns from large volumes of complex visual data. This technology has garnered substantial interest in the field of neuro-oncology as a promising tool to enhance medical imaging throughput and analysis. A multitude of methods harnessing MRI-based CNNs have been proposed for brain tumor segmentation, classification, and prognosis prediction. They are often applied to gliomas, the most common primary brain cancer, to classify subtypes with the goal of guiding therapy decisions. Additionally, the difficulty of repeating brain biopsies to evaluate treatment response in the setting of often confusing imaging findings provides a unique niche for CNNs to help distinguish the treatment response to gliomas. For example, glioblastoma, the most aggressive type of brain cancer, can grow due to poor treatment response, can appear to grow acutely due to treatment-related inflammation as the tumor dies (pseudo-progression), or falsely appear to be regrowing after treatment as a result of brain damage from radiation (radiation necrosis). CNNs are being applied to separate this diagnostic dilemma. This review provides a detailed synthesis of recent DL methods and applications for intratumor segmentation, glioma classification, and prognosis prediction. Furthermore, this review discusses the future direction of MRI-based CNN in the field of neuro-oncology and challenges in model interpretability, data availability, and computation efficiency.

深度学习(DL)有望重新定义医学图像的处理和分析方式。卷积神经网络(CNN)是一种特定类型的深度学习架构,在高通量处理方面表现出色,可从大量复杂的视觉数据中有效提取相关诊断模式。这项技术在神经肿瘤学领域引起了极大的兴趣,被认为是提高医学成像吞吐量和分析能力的有效工具。利用基于 MRI 的 CNN 进行脑肿瘤分割、分类和预后预测的方法层出不穷。它们通常应用于胶质瘤(最常见的原发性脑癌)的亚型分类,目的是指导治疗决策。此外,在成像结果经常令人困惑的情况下,重复脑活检以评估治疗反应存在困难,这为 CNN 提供了一个独特的利基,有助于区分胶质瘤的治疗反应。例如,胶质母细胞瘤是侵袭性最强的脑癌类型,它可能因治疗反应不佳而生长,也可能因治疗相关炎症导致肿瘤坏死而出现急性生长(假性进展),或因辐射造成脑损伤而在治疗后出现假性再生(辐射坏死)。目前正在应用 CNN 解决这一诊断难题。本综述详细综述了最近用于肿瘤内分割、胶质瘤分类和预后预测的 DL 方法和应用。此外,本综述还讨论了基于 MRI 的 CNN 在神经肿瘤学领域的未来发展方向,以及在模型可解释性、数据可用性和计算效率方面所面临的挑战。
{"title":"Convolutional Neural Networks for Glioma Segmentation and Prognosis: A Systematic Review.","authors":"Janette Herr, Radka Stoyanova, Eric Albert Mellon","doi":"10.1615/CritRevOncog.2023050852","DOIUrl":"10.1615/CritRevOncog.2023050852","url":null,"abstract":"<p><p>Deep learning (DL) is poised to redefine the way medical images are processed and analyzed. Convolutional neural networks (CNNs), a specific type of DL architecture, are exceptional for high-throughput processing, allowing for the effective extraction of relevant diagnostic patterns from large volumes of complex visual data. This technology has garnered substantial interest in the field of neuro-oncology as a promising tool to enhance medical imaging throughput and analysis. A multitude of methods harnessing MRI-based CNNs have been proposed for brain tumor segmentation, classification, and prognosis prediction. They are often applied to gliomas, the most common primary brain cancer, to classify subtypes with the goal of guiding therapy decisions. Additionally, the difficulty of repeating brain biopsies to evaluate treatment response in the setting of often confusing imaging findings provides a unique niche for CNNs to help distinguish the treatment response to gliomas. For example, glioblastoma, the most aggressive type of brain cancer, can grow due to poor treatment response, can appear to grow acutely due to treatment-related inflammation as the tumor dies (pseudo-progression), or falsely appear to be regrowing after treatment as a result of brain damage from radiation (radiation necrosis). CNNs are being applied to separate this diagnostic dilemma. This review provides a detailed synthesis of recent DL methods and applications for intratumor segmentation, glioma classification, and prognosis prediction. Furthermore, this review discusses the future direction of MRI-based CNN in the field of neuro-oncology and challenges in model interpretability, data availability, and computation efficiency.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical Management of the Neck in Oral Cavity Squamous Cell Carcinoma. 口腔鳞状细胞癌的颈部手术治疗。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.1615/CritRevOncog.2023050817
Olivia Mihulka, Eric Nisenbaum, Elizabeth Nicolli

Oral cavity cancer remains a significant cause of morbidity and mortality globally, with a poor prognosis once the disease has metastasized to cervical lymph nodes. The anatomy of lymphatic drainage in the neck gives us a roadmap to follow when assessing for metastasis, although the predictive factors are still not well understood. The mainstay of treatment continues to be neck dissection. However, there is much debate on the management of the clinically negative neck. The necessity of elective neck dissection has been questioned in recent years, with other options such as sentinel lymph node biopsy gaining popularity. This review will explore the aspects of surgical management of the neck in oral cavity cancer and highlights the further research that needs to be done.

口腔癌仍然是全球发病率和死亡率的重要原因,一旦转移到颈部淋巴结,预后很差。颈部淋巴引流的解剖结构为我们评估转移提供了路线图,尽管预测因素仍不十分清楚。治疗的主要方法仍然是颈部清扫术。然而,对于临床阴性颈部淋巴结的处理仍存在很多争议。近年来,随着前哨淋巴结活检等其他方法的流行,选择性颈部切除术的必要性受到质疑。本综述将探讨口腔癌颈部手术治疗的各个方面,并强调需要进一步开展的研究。
{"title":"Surgical Management of the Neck in Oral Cavity Squamous Cell Carcinoma.","authors":"Olivia Mihulka, Eric Nisenbaum, Elizabeth Nicolli","doi":"10.1615/CritRevOncog.2023050817","DOIUrl":"10.1615/CritRevOncog.2023050817","url":null,"abstract":"<p><p>Oral cavity cancer remains a significant cause of morbidity and mortality globally, with a poor prognosis once the disease has metastasized to cervical lymph nodes. The anatomy of lymphatic drainage in the neck gives us a roadmap to follow when assessing for metastasis, although the predictive factors are still not well understood. The mainstay of treatment continues to be neck dissection. However, there is much debate on the management of the clinically negative neck. The necessity of elective neck dissection has been questioned in recent years, with other options such as sentinel lymph node biopsy gaining popularity. This review will explore the aspects of surgical management of the neck in oral cavity cancer and highlights the further research that needs to be done.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preface: Artificial Intelligence and the Revolution of Oncological Imaging. 序言:人工智能与肿瘤成像革命。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.1615/CritRevOncog.v29.i2.30
Maurizio Cè, Michaela Cellina
{"title":"Preface: Artificial Intelligence and the Revolution of Oncological Imaging.","authors":"Maurizio Cè, Michaela Cellina","doi":"10.1615/CritRevOncog.v29.i2.30","DOIUrl":"https://doi.org/10.1615/CritRevOncog.v29.i2.30","url":null,"abstract":"","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140176785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuroplasticity: Pathophysiology and Role in Major Depressive Disorder. 神经可塑性:病理生理学及在重度抑郁症中的作用。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.1615/CritRevOncog.2024051197
Sreeharshini Kadiyala, Priyamvada Bhamidipati, Rama Rao Malla

Neuroplasticity is characterized by the brain's ability to change its activity in response to extrinsic and intrinsic factors and is thought to be the mechanism behind all brain functions. Neuroplasticity causes structural and functional changes on a molecular level, specifically the growth of different regions in the brain and changes in synaptic and post-synaptic activities. The four types of neuroplasticity are homologous area adaption, compensatory masquerade, cross-modal reassignment, and map expansion. All of these help the brain work around injuries or new information inputs. In addition to baseline physical functions, neuroplasticity is thought to be the basis of emotional and mental regulations and the impairment of it can cause various mental illnesses. Concurrently, these mental illnesses further the damage of synaptic plasticity in the brain. Major depressive disorder (MDD) is one of the most common mental illnesses. It is affected by and accelerates the impairment of neuroplasticity. It is characterized by a chronically depressed state of mind that can impact the patient's daily life, including work life and interests. This review will focus on highlighting the physiological aspects of the disease and the role of neuroplasticity in the pathogenesis and pathology of the disorder. Moreover, the role of monoamine regulation and ketamine uptake will be discussed in terms of their antidepressant effects on the outcomes of MDD.

神经可塑性的特点是大脑能够根据外在和内在因素改变其活动,被认为是所有大脑功能背后的机制。神经可塑性在分子水平上引起结构和功能的变化,特别是大脑中不同区域的生长以及突触和突触后活动的变化。神经可塑性的四种类型是同源区域适应、补偿性伪装、跨模态重新分配和地图扩展。所有这些都有助于大脑在受伤或新信息输入的情况下工作。除了基本的生理功能外,神经可塑性还被认为是情绪和精神调节的基础,其受损会导致各种精神疾病。同时,这些精神疾病会进一步损害大脑的突触可塑性。重度抑郁症(MDD)是最常见的精神疾病之一。它受到神经可塑性损伤的影响,并加速神经可塑性损伤。它的特点是长期处于抑郁的精神状态,会影响患者的日常生活,包括工作生活和兴趣爱好。本综述将重点介绍该疾病的生理方面以及神经可塑性在该疾病的发病机制和病理学中的作用。此外,还将讨论单胺调节和氯胺酮摄取对 MDD 治疗结果的抗抑郁作用。
{"title":"Neuroplasticity: Pathophysiology and Role in Major Depressive Disorder.","authors":"Sreeharshini Kadiyala, Priyamvada Bhamidipati, Rama Rao Malla","doi":"10.1615/CritRevOncog.2024051197","DOIUrl":"10.1615/CritRevOncog.2024051197","url":null,"abstract":"<p><p>Neuroplasticity is characterized by the brain's ability to change its activity in response to extrinsic and intrinsic factors and is thought to be the mechanism behind all brain functions. Neuroplasticity causes structural and functional changes on a molecular level, specifically the growth of different regions in the brain and changes in synaptic and post-synaptic activities. The four types of neuroplasticity are homologous area adaption, compensatory masquerade, cross-modal reassignment, and map expansion. All of these help the brain work around injuries or new information inputs. In addition to baseline physical functions, neuroplasticity is thought to be the basis of emotional and mental regulations and the impairment of it can cause various mental illnesses. Concurrently, these mental illnesses further the damage of synaptic plasticity in the brain. Major depressive disorder (MDD) is one of the most common mental illnesses. It is affected by and accelerates the impairment of neuroplasticity. It is characterized by a chronically depressed state of mind that can impact the patient's daily life, including work life and interests. This review will focus on highlighting the physiological aspects of the disease and the role of neuroplasticity in the pathogenesis and pathology of the disorder. Moreover, the role of monoamine regulation and ketamine uptake will be discussed in terms of their antidepressant effects on the outcomes of MDD.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141580971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Cavity Squamous Cell Carcinoma: Review of Pathology, Diagnosis, and Management. 口腔鳞状细胞癌:病理学、诊断和处理回顾。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.1615/CritRevOncog.2023050055
Benjamin J Rich, Stuart E Samuels, Gregory A Azzam, Gregory Kubicek, Laura Freedman

Squamous cell carcinoma of the oral cavity presents a significant global health burden, primarily due to risk factors such as tobacco smoking, smokeless tobacco use, heavy alcohol consumption, and betel quid chewing. Common clinical manifestations of oral cavity cancer include visible lesions and sores, often accompanied by pain in advanced stages. Diagnosis relies on a comprehensive assessment involving detailed history, physical examination, and biopsy. Ancillary imaging studies and functional evaluations aid in accurate staging and facilitate treatment planning. Prognostic information is obtained from histopathological factors, such as tumor grade, depth of invasion, lymphovascular invasion, and perineural invasion. Notably, lymph node metastasis, found in approximately half of the patients, carries significant prognostic implications. Effective management necessitates a multidisciplinary approach to optimize patient outcomes. Surgical resection is the backbone of treatment, aimed at complete tumor removal while preserving functional outcomes. Adjuvant therapies, including radiation and chemotherapy, are tailored according to pathological factors. Further work in risk stratification and treatment is necessary to optimize outcomes in squamous cell carcinoma of the oral cavity.

口腔鳞状细胞癌给全球健康带来了巨大负担,这主要是由于吸烟、使用无烟烟草、大量饮酒和嚼槟榔等风险因素造成的。口腔癌的常见临床表现包括明显的病变和溃疡,晚期患者通常伴有疼痛。诊断有赖于全面的评估,包括详细的病史、体格检查和活组织检查。辅助影像学检查和功能评估有助于准确分期和制定治疗计划。预后信息可从组织病理学因素中获得,如肿瘤分级、浸润深度、淋巴管浸润和神经周围浸润。值得注意的是,淋巴结转移在约半数患者中发现,对预后有重要影响。有效的治疗需要采用多学科方法,以优化患者的预后。手术切除是治疗的支柱,目的是彻底切除肿瘤,同时保留功能性结果。辅助治疗包括放疗和化疗,根据病理因素量身定制。为优化口腔鳞状细胞癌的治疗效果,有必要进一步开展风险分层和治疗工作。
{"title":"Oral Cavity Squamous Cell Carcinoma: Review of Pathology, Diagnosis, and Management.","authors":"Benjamin J Rich, Stuart E Samuels, Gregory A Azzam, Gregory Kubicek, Laura Freedman","doi":"10.1615/CritRevOncog.2023050055","DOIUrl":"10.1615/CritRevOncog.2023050055","url":null,"abstract":"<p><p>Squamous cell carcinoma of the oral cavity presents a significant global health burden, primarily due to risk factors such as tobacco smoking, smokeless tobacco use, heavy alcohol consumption, and betel quid chewing. Common clinical manifestations of oral cavity cancer include visible lesions and sores, often accompanied by pain in advanced stages. Diagnosis relies on a comprehensive assessment involving detailed history, physical examination, and biopsy. Ancillary imaging studies and functional evaluations aid in accurate staging and facilitate treatment planning. Prognostic information is obtained from histopathological factors, such as tumor grade, depth of invasion, lymphovascular invasion, and perineural invasion. Notably, lymph node metastasis, found in approximately half of the patients, carries significant prognostic implications. Effective management necessitates a multidisciplinary approach to optimize patient outcomes. Surgical resection is the backbone of treatment, aimed at complete tumor removal while preserving functional outcomes. Adjuvant therapies, including radiation and chemotherapy, are tailored according to pathological factors. Further work in risk stratification and treatment is necessary to optimize outcomes in squamous cell carcinoma of the oral cavity.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disparities in Electronic Cigarette Use: A Narrative Review. 电子烟使用中的差异:叙述性综述。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-01 DOI: 10.1615/CritRevOncog.2024051128
Kyle Edwards, Aysswarya Manoharan, Taghrid Asfar, Samuel Kareff, Gilberto Lopes, Estelamari Rodriguez, Coral Olazagasti

The prevalence of electronic cigarette use has been declared an epidemic by the U.S. Surgeon General in 2018, particularly among youth aged 18-24 years old. Little is known about the differential use of e-cigarettes by different groups. PubMed, Cochrane, and Google Scholar were used to find relevant articles. A total of 77 articles were included. The extant literature reveals disparities in e-cigarette use by race/ethnicity and sexuality/gender. There are conflicting conclusions regarding disparities by socioeconomic status.

2018 年,美国卫生总监宣布电子烟的使用盛行已成为一种流行病,尤其是在 18-24 岁的青少年中。人们对不同群体使用电子烟的差异知之甚少。我们使用PubMed、Cochrane和谷歌学术搜索相关文章。共收录了 77 篇文章。现有文献揭示了不同种族/民族和性/性别使用电子烟的差异。关于社会经济地位的差异,结论相互矛盾。
{"title":"Disparities in Electronic Cigarette Use: A Narrative Review.","authors":"Kyle Edwards, Aysswarya Manoharan, Taghrid Asfar, Samuel Kareff, Gilberto Lopes, Estelamari Rodriguez, Coral Olazagasti","doi":"10.1615/CritRevOncog.2024051128","DOIUrl":"10.1615/CritRevOncog.2024051128","url":null,"abstract":"<p><p>The prevalence of electronic cigarette use has been declared an epidemic by the U.S. Surgeon General in 2018, particularly among youth aged 18-24 years old. Little is known about the differential use of e-cigarettes by different groups. PubMed, Cochrane, and Google Scholar were used to find relevant articles. A total of 77 articles were included. The extant literature reveals disparities in e-cigarette use by race/ethnicity and sexuality/gender. There are conflicting conclusions regarding disparities by socioeconomic status.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Critical Reviews in Oncogenesis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1